Premium
Effect of subcutaneous insulin detemir on glucose flux, lipolysis and electroencephalography in type 1 diabetes
Author(s) -
Herring R.,
Knight R.,
ShojaeeMoradie F.,
Johnsen S.,
Umpleby A. M.,
Jackson N.,
Jones R.,
Dijk D.J.,
RussellJones D. L.
Publication year - 2015
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12553
Subject(s) - insulin detemir , medicine , endocrinology , lipolysis , chemistry , glycerol , type 2 diabetes , diabetes mellitus , adipose tissue , biochemistry , basal insulin
The aim of the present study was to investigate the effects of subcutaneous detemir on glucose flux, lipid metabolism and brain function. Twelve people with type 1 diabetes received, in random order, 0.5 units/kg body weight detemir or NPH insulin. Glucose concentration was clamped at 5 mmol/l then increased to 10 mmol/l. Glucose production rate (glucose Ra ), glucose uptake (glucose Rd ) and glycerol production (glycerol Ra ) were measured with a constant intravenous infusion of [6, 6 2 H 2 ]glucose and [ 2 H 5 ]glycerol. Electroencephalography direct current ( DC ) and alternating current ( AC ) potentials were measured. While detemir induced similar effects on glucose Ra , glucose Rd and glycerol Ra during euglycaemia compared with NPH , it triggered a distinct negative shift in DC potentials, with a significant treatment effect in frontal cerebrocortical channels (p < 0.001). AC spectral power showed significant differences in theta and alpha frequencies during euglycaemia (p = 0.03). Subcutaneous detemir exerts different effects on brain function when compared with NPH in people with type 1 diabetes. This may be an important mechanism behind the limitation of weight gain with detemir.